Celularity Faces Second Nasdaq Delisting Warning as Bid Price Sinks Below $1
CELU sits 20% above its 52-week low of $0.56.
Summary
Celularity has received a second Nasdaq delisting notice, this time for its stock price falling below $1.00. To remain listed, the company must now remedy both its market value and bid price deficiencies by January 19, 2027.
Key Events · Legal and Risk Events · CELU
-
Second Nasdaq Delisting Notice
On July 23, 2026, Nasdaq notified Celularity that its stock price had closed below $1.00 for 30 consecutive business days, violating the minimum bid price rule. This deficiency is separate from the existing market value shortfall.
-
Compliance Deadline Set
The company has 180 calendar days, until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. An additional 180-day grace period may be available if certain conditions are met.
-
Precarious Financial Position
With a market cap of $19.4 million and a stock price of $0.67, Celularity falls far short of both the $35 million market value and $1.00 bid price requirements. A recent $1 million bridge loan from a related party highlights the company's cash constraints.
-
Reverse Split Likely
Given the current share price, regaining compliance without a reverse stock split appears unlikely. A reverse split would mechanically lift the per-share price but often triggers further declines and shareholder dilution.
Analysis · CELU · Life Sciences
A new Nasdaq deficiency notice has landed on Celularity after its stock price closed below $1.00 for 30 consecutive business days, compounding an existing delisting threat tied to market value. The company must now clear two separate hurdles: a $35 million market value requirement and a $1.00 minimum bid price. With a market cap of just $19.4 million and shares trading at $0.67, regaining compliance will likely demand a reverse stock split—a move that frequently erodes shareholder value. The clock runs until January 19, 2027, but a recent $1 million bridge loan and persistent cash burn underscore the urgency.
At the time of this filing, CELU was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.4M. The 52-week trading range was $0.56 to $4.31. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.